IN2014DN07875A - - Google Patents
Info
- Publication number
- IN2014DN07875A IN2014DN07875A IN7875DEN2014A IN2014DN07875A IN 2014DN07875 A IN2014DN07875 A IN 2014DN07875A IN 7875DEN2014 A IN7875DEN2014 A IN 7875DEN2014A IN 2014DN07875 A IN2014DN07875 A IN 2014DN07875A
- Authority
- IN
- India
- Prior art keywords
- peptide
- therapeutic agent
- ssvlyggppsaa
- histone
- conjugate
- Prior art date
Links
- 239000003814 drug Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 108010033040 Histones Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012035965A JP2015117181A (ja) | 2012-02-22 | 2012-02-22 | 敗血症治療剤 |
| PCT/JP2013/054551 WO2013125687A1 (ja) | 2012-02-22 | 2013-02-22 | 炎症疾患治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07875A true IN2014DN07875A (enrdf_load_stackoverflow) | 2015-04-24 |
Family
ID=49005863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7875DEN2014 IN2014DN07875A (enrdf_load_stackoverflow) | 2012-02-22 | 2013-02-22 |
Country Status (8)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103534271B (zh) | 2010-08-20 | 2016-06-22 | 学校法人城西大学 | 有免疫抑制活性的单克隆抗体或其抗原结合片段 |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| EP3436482A4 (en) * | 2016-03-29 | 2020-03-11 | OBI Pharma, Inc. | ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS |
| CA3038021A1 (en) * | 2016-09-23 | 2018-03-29 | Tfk Co., Ltd. | Compound or salt thereof, anti-inflammatory agent, anti-cancer agent against lung cancer, method of producing compound or salts thereof, method of treating inflammatory diseases and method of treating lung cancer |
| CN119912525B (zh) * | 2025-04-02 | 2025-07-29 | 天津不二蛋白有限公司 | 含抗炎症肽序列的大豆蛋白水解物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070073754A (ko) * | 2004-09-03 | 2007-07-10 | 아마테라스파마 가부시키가이샤 | 항-히스톤 ｈ1 모노크로날 항체 및 그것을 생성할 수 있는하이브리도마 |
| US20100324469A1 (en) * | 2007-10-04 | 2010-12-23 | Josai University Corporation | Drug product, a method of administrating a vaccine using the drug product, and an apparatus for iontophoresis |
| WO2009061918A1 (en) * | 2007-11-06 | 2009-05-14 | Oklahoma Medical Research Foundation | Extracellular histones as biomarkers for prognosis and molecular targets for therapy |
| CN103534271B (zh) * | 2010-08-20 | 2016-06-22 | 学校法人城西大学 | 有免疫抑制活性的单克隆抗体或其抗原结合片段 |
-
2012
- 2012-02-22 JP JP2012035965A patent/JP2015117181A/ja active Pending
-
2013
- 2013-02-22 CN CN201380020995.1A patent/CN104379165B/zh not_active Expired - Fee Related
- 2013-02-22 US US14/380,292 patent/US20150079090A1/en not_active Abandoned
- 2013-02-22 WO PCT/JP2013/054551 patent/WO2013125687A1/ja active Application Filing
- 2013-02-22 IN IN7875DEN2014 patent/IN2014DN07875A/en unknown
- 2013-02-22 KR KR1020147024978A patent/KR102159412B1/ko not_active Expired - Fee Related
- 2013-02-22 TW TW102106211A patent/TWI605059B/zh not_active IP Right Cessation
- 2013-02-22 EP EP13751092.1A patent/EP2815763B1/en not_active Not-in-force
-
2016
- 2016-10-13 US US15/292,450 patent/US20170096478A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR102159412B1 (ko) | 2020-09-23 |
| TW201350502A (zh) | 2013-12-16 |
| EP2815763A4 (en) | 2015-07-22 |
| US20150079090A1 (en) | 2015-03-19 |
| EP2815763A1 (en) | 2014-12-24 |
| WO2013125687A1 (ja) | 2013-08-29 |
| TWI605059B (zh) | 2017-11-11 |
| CN104379165A (zh) | 2015-02-25 |
| KR20140138699A (ko) | 2014-12-04 |
| US20170096478A1 (en) | 2017-04-06 |
| JP2015117181A (ja) | 2015-06-25 |
| EP2815763B1 (en) | 2018-06-13 |
| CN104379165B (zh) | 2018-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| PH12014500089A1 (en) | Antibodies that bind to ox40 and their uses | |
| TN2014000120A1 (en) | Cd27l antigen binding proteins | |
| MX360741B (es) | Constructos de polipéptidos y sus usos. | |
| NZ610267A (en) | A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use | |
| NZ607969A (en) | Cd33 binding agents | |
| IN2014KN01715A (enrdf_load_stackoverflow) | ||
| PH12014501783B1 (en) | Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody | |
| UA111818C2 (uk) | Антитіло проти csf-1r | |
| NZ607710A (en) | 4-1bb binding molecules | |
| MX2014001375A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| AR096364A1 (es) | Anticuerpos receptores de antitransferina y métodos de uso | |
| MX357193B (es) | Moleculas de union anti-alfa sinucleina. | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012008998A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX342291B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| NZ630847A (en) | Anti-sema4d antibodies and epitopes | |
| SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
| UA113623C2 (uk) | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| IN2014DN07875A (enrdf_load_stackoverflow) | ||
| EA201270701A1 (ru) | Ингибирующие металлопротеины антитела | |
| IN2013MN00513A (enrdf_load_stackoverflow) | ||
| WO2010127180A3 (en) | Dc-stamp antibodies |